DBV Technologies | DBVT - Debt


DBV Technologies reported $6.1M in Debt for its fiscal quarter ending in March of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 1.44B 833.74M Mar/2026
DBV Technologies USD 6.1M 2.49M Mar/2026
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Insmed USD 725.8M 1.82M Jun/2026
Ionis Pharmaceuticals USD 1.91B 425.5M Jun/2026
Neurocrine Biosciences USD 406.2M 9.1M Mar/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
United Therapeutics USD 200M 100M Mar/2025